283 related articles for article (PubMed ID: 34600745)
1. Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022.
Hahr AJ; Molitch ME
Am J Kidney Dis; 2022 May; 79(5):728-736. PubMed ID: 34600745
[TBL] [Abstract][Full Text] [Related]
2. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
Tong L; Adler S
Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921
[TBL] [Abstract][Full Text] [Related]
3. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798
[TBL] [Abstract][Full Text] [Related]
4. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY
JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430
[TBL] [Abstract][Full Text] [Related]
5. Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia Risk.
Htoo PT; Paik JM; Alt E; Kim DH; Wexler DJ; Kim SC; Patorno E
J Gerontol A Biol Sci Med Sci; 2023 Dec; 78(12):2426-2434. PubMed ID: 36866496
[TBL] [Abstract][Full Text] [Related]
6. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Roussel R; Lorraine J; Rodriguez A; Salaun-Martin C
Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type 2 diabetes: a retrospective cohort analysis.
McCormick TA; Kramer J; Liles EG; Amos Q; Martin JP; Adams JL
BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38719507
[TBL] [Abstract][Full Text] [Related]
8. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.
Drake T; Landsteiner A; Langsetmo L; MacDonald R; Anthony M; Kalinowski C; Ullman K; Billington CJ; Kaka A; Sultan S; Wilt TJ
Ann Intern Med; 2024 May; 177(5):618-632. PubMed ID: 38639549
[TBL] [Abstract][Full Text] [Related]
9. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
10. The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists.
Serowik TC; Pantalone KM
J Osteopath Med; 2024 Mar; 124(3):127-135. PubMed ID: 37921061
[TBL] [Abstract][Full Text] [Related]
11. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
12. Trends in antidiabetes medication use among hospitalised patients with type 2 diabetes: a retrospective single-centre cohort study.
Meier N; Laager R; Gregoriano C; Schütz P; Mueller B; Struja T; Kutz A
BMJ Open; 2024 Jul; 14(6):e084526. PubMed ID: 38950998
[TBL] [Abstract][Full Text] [Related]
13. Trends in Prescribing Preferences for Antidiabetic Medications Among Patients With Type 2 Diabetes in the U.K. With and Without Chronic Kidney Disease, 2006-2020.
Liaw J; Harhay M; Setoguchi S; Gerhard T; Dave CV
Diabetes Care; 2022 Oct; 45(10):2316-2325. PubMed ID: 35984049
[TBL] [Abstract][Full Text] [Related]
14. High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database.
Fried L; Schmedt N; Folkerts K; Bowrin K; Raad H; Batech M; Kovesdy C
Nephrol Dial Transplant; 2023 Feb; 38(3):630-643. PubMed ID: 35389468
[TBL] [Abstract][Full Text] [Related]
15. [Newer anti - diabetic therapies and chronic kidney disease].
Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
[TBL] [Abstract][Full Text] [Related]
16. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
[TBL] [Abstract][Full Text] [Related]
17. Glucose-Lowering Medications and Cardiovascular Outcomes.
Shanmugasundaram M; Pineda JRE; Murugapandian S
Curr Cardiol Rep; 2021 Mar; 23(4):24. PubMed ID: 33655453
[TBL] [Abstract][Full Text] [Related]
18. Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.
Li Y; Hu Y; Huyan X; Chen K; Li B; Gu W; Mu Y
Front Endocrinol (Lausanne); 2022; 13():1003263. PubMed ID: 36353233
[TBL] [Abstract][Full Text] [Related]
19. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
20. Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey.
Nouraei H; Leiter LA; Tan MK; Langer A; Teoh H; Cheng AYY; Wald R; Connelly KA; Goodman SG; Yan AT
Can J Diabetes; 2021 Dec; 45(8):743-749. PubMed ID: 33839025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
